Invasion and Metastasis Lab

Our lab uses intravital imaging approaches to pinpoint critical events that drive tumour invasion and metastasis | @GarvanInstitute @KinghornCancer @UNSW

[Invasion and Metastasis Lab @Timpson_Lab]

Our latest publication in @ScienceAdvances is officially out!
Here, we target the NPY/NPY1R signalling axis to lessen metastatic burden of mutant p53-dependent #PancreaticCancer 🔬👩🏼‍🔬
Check it out here:
https://t.co/plZXXue5Lf
@GarvanInstitute @Timpson_Lab

[Amplia Therapeutics @ampliatx]

$ATX | #Amplia has enrolled and has begun dosing the first patient in the Company's new pancreatic cancer trial, exploring narmafotinib in combination with FOLFIRINOX in newly diagnosed advanced #pancreaticcancer patients. Read the ASX release: https://t.co/zW6UQPUMuk

[Garvan Institute of Medical Research @GarvanInstitute]

Join us in our mission to save lives and transform the future of pancreatic cancer treatment. 💜

Click here to find out more: https://t.co/n0ALg31X8W

#PancreaticCancer #PancreaticCancerAwareness #garvan #PurpleForAPurpose #FightPancreaticCancer #PurpleOurWorld

[Garvan Institute of Medical Research @GarvanInstitute]

We’re excited to share news from the @ampliatx ACCENT trial: one patient with advanced pancreatic cancer showed no remaining cancer cells after treatment. This complete response is extremely rare in this aggressive cancer type.

[Amplia Therapeutics @ampliatx]

$ATX | #Amplia has announced that a second patient enrolled in the ACCENT trial has recorded a confirmed complete response (CR). Read the ASX release: https://t.co/dz0euPzDVO #pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX

[Amplia Therapeutics @ampliatx]

Did you catch this summary of the latest results from Amplia's ACCENT clinical trial in Small Caps this week? Take a look: https://t.co/oBd8MReMyq $ATX #Amplia #pancreaticcancer #clinicaltrial #pharma #biotech #innovation

[Amplia Therapeutics @ampliatx]

$ATX UPDATE | #Amplia has today announced that a patient from ACCENT clinical trial in advanced #pancreatic cancer has now recorded a pathological complete response (pCR) - an extremely rare observation in this patient population. Read the #ASX release: https://t.co/uBdwuhWsGi

[Amplia Therapeutics @ampliatx]

#Amplia has made headlines today following the announcement of a “pathological complete response” in an advanced #pancreaticcancer patient today. Biotech journalist Tim Boreham noted that Amplia shares had soared almost 50% following the news. Take a look: https://t.co/pFovstgPKz

[Extracellular Matrix News @ExtracellMatrix]

Integrins provide a bridge between cancer cells and the #ECM, playing a role in every stage of disease progression. 🌉

Drs. James Conway & Johanna Ivaska reveal the importance of integrin phosphorylation for cancer cell invasion. @NatureCellBio

🔗 https://t.co/LZKn5pd1Na

[Amplia Therapeutics @ampliatx]

$ATX | #Amplia has today announced that trial initiation activities for the planned pancreatic cancer trial in the US have begun. Read the ASX release: https://t.co/V5Fmmszz0g
#pancreaticcancer #clinicaltrial #drugdiscovery #innovation #cancertreatment

[Invasion and Metastasis Lab @Timpson_Lab]

Check out our latest work on @7NewsSydney 🎥
Here, we report on targeting the NPY/NPY1R signalling axis to lessen #PancreaticCancer metastasis🔬👩🏼‍🔬
@GarvanInstitute
Check it out here:
https://t.co/GtBkav8otQ

[ANZSCDB @ANZSCDB]

📢 Hunter Meeting 2025 - Abstract submissions close on Friday 14th February 2025, 5pm AEST!

The Hunter Meeting promises a fabulous line-up of international and national speakers in 2025.

Submit your abstract and register to attend!

Link: https://t.co/58AbpP5JSA

[Invasion and Metastasis Lab @Timpson_Lab]

Want to join our lab and contribute to world-class cancer research in Sydney? We are looking for a new research assistant! 🔬🧫 Apply here: https://t.co/c9DnKESDMV

[Amplia Therapeutics @ampliatx]

Today - on #WorldCancerDay - we're grateful to our research collaborators, whose expertise and dedication make our clinical trials possible. Equal gratitude goes to the trial participants, and their families, who share our hope of improving outcomes for patients. #ATX #Amplia

[The Cesare Lab @TheCesareLab]

1/Delighted to announce the newest paper from our lab, “Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage”, is out today in @NatureCellBio, https://t.co/UoMWePsnYn.

[Garvan Institute of Medical Research @GarvanInstitute]

Congratulations to Dr Brooke Pereira on receiving a Fulbright Future Scholarship. Her work in pancreatic cancer research Garvan will benefit from this international opportunity. #FulbrightScholar #CancerResearch

[Centre for Cancer Biology @CCB_Research]

Congratulations to CCB’s @dr_phil_gregory, @QuentenSchwarz and @TMEM_Samuel, who have been awarded @NHMRC Ideas Grant funding for 2025. Well done!

[Brooke Pereira, PhD @brooke_pereira_]

I'm very pleased to share that I have received a NHMRC Ideas grant to explore targeting fibrosis in combination with chemotherapy to improve treatment efficacy in pancreatic cancer. Also a big thank you to the CI/AI team - cant wait to get started! @Timpson_Lab @GarvanInstitute

[Amplia Therapeutics @ampliatx]

VIDEO | #Amplia CEO & MD Dr Chris Burns and COO Dr Rhiannon Jones discuss the significance of Amplia’s latest clinical data from the ACCENT trial, and what investors can expect from Amplia in 2025.
Take a look: https://t.co/NU090hLK8p $ATX #clinicaltrial #pancreaticcancer #pharma

[Cancer Institute NSW @cancerNSW]

A $3.75 million grant from the Institute is supporting an innovative ‘personalised medicine framework’ that is giving hope to people with pancreatic cancer. Learn more about its progress: https://t.co/Et4JvDW3my